Back to Search
JOHN HOLCOMBE, MD
MD
Internal Medicine Physician
NPI: 1386671501Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
22194(AL)
Research & Publications (20)
Healthcare charges and utilization associated with diabetic neuropathy: impact of Type 1 diabetes and presence of other diabetes-related complications and comorbidities.
PMID 19125762·Diabet Med·2009
8-other
Magnetic gamma-Fe(2)O(3) nanoparticles coated with poly-l-cysteine for chelation of As(III), Cu(II), Cd(II), Ni(II), Pb(II) and Zn(II).
PMID 18571848·J Hazard Mater·2009
8-other
Comparing clinical and economic characteristics between commercially-insured patients with diabetic neuropathy and demographically-matched diabetic controls.
PMID 19232033·Curr Med Res Opin·2009
4-observational
Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
PMID 18555933·Clin Ther·2008
4-observational
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
PMID 18786299·Curr Med Res Opin·2008
3-trial
Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes.
PMID 18394265·Curr Med Res Opin·2008
3-trial
A 'turn-on' FRET peptide sensor based on the mercury binding protein MerP.
PMID 18087615·Analyst·2008
7-preclinical
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
PMID 18053320·Curr Med Res Opin·2008
3-trial
Metal binding characterization and conformational studies using Raman microscopy of resin-bound poly(aspartic acid).
PMID 17249637·Anal Chem·2007
8-other
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
PMID 17379054·Clin Ther·2007
4-observational
A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
PMID 17157120·Clin Ther·2006
2-rct
Management of Type 2 diabetes: the role of incretin mimetics.
PMID 17020435·Expert Opin Pharmacother·2006
6-review
Poly(L-cysteine) as an electrochemically modifiable ligand for trace metal chelation.
PMID 15623275·Anal Chem·2005
8-other
Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
PMID 15823767·Clin Ther·2004
3-trial
Factors influencing health care workers' adherence to work site tuberculosis screening and treatment policies.
PMID 15573052·Am J Infect Control·2004
8-other
Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents.
PMID 12017407·Clin Ther·2002
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 619 19TH STREET SOUTH
BIRMINGHAM, AL 35255 - Phone
- (205) 934-6600
Quick Facts
- NPI
- 1386671501
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile